Company Description
Curative Biotechnology, Inc., a development-stage biomedical company, develops, licenses, and commercializes pharmaceutical products and medical devices.
The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease.
Its pipeline candidates include Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504 a novel immune therapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor.
The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine.
Curative Biotechnology, Inc. is headquartered in Palm Beach Gardens, Florida.
| Country | United States |
| Founded | 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | I. Richard Garr Esq., J.D. |
Contact Details
Address: 1825 Nw Corporate Blvd, Suite 110 Boca Raton, Florida 33431 United States | |
| Phone | 800-526-8006 |
| Website | curativebiotech.com |
Stock Details
| Ticker Symbol | CUBT |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001400271 |
| CUSIP Number | 23128N108 |
| ISIN Number | US23128N1081 |
| Employer ID | 72-1550658 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| I. Richard Garr Esq., J.D. | Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer and General Counsel |
| Paul M. Michaels | President and Executive Chairman |
| Pam Bisikirski | Vice President of Communications |
| Dr. Ronald Bordens Ph.D. | Executive Vice President of Process Product Drug Development and Member of Scientific and Clinical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 1, 2024 | RW | Filing |
| Jan 25, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 18, 2023 | D | Notice of Exempt Offering of Securities |
| Jan 13, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 9, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 1, 2022 | 8-A12B/A | Filing |
| Nov 30, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 16, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 7, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |